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Introduction: Evidence that has been published in the last decade
indicates that in patients with limited-stage small-cell lung cancer
(SCLC), hyperfractionated accelerated thoracic radiotherapy (RT)
given twice daily and prophylactic cranial irradiation (PCI) have
each separately improved survival. Concerns about the toxicities
associated with these treatments and uncertainty about their impact
on survival outside the trial setting may have restricted the extent to
which they have been incorporated into standard treatment proto-
cols. We have reviewed the experience at Peter MacCallum Cancer
Centre to determine the tolerability of these treatments in routine
practice and to determine their effects on survival.
Methods: A retrospective review of patients with limited-stage
SCLC receiving a radical course of thoracic RT between June 1998
and May 2002, including either conventional fractionation at 50 Gy
for 5 weeks, or hyperfractionated accelerated RT at 45 Gy for 3
weeks. Patients achieving a complete response were offered PCI at
36 Gy in 18 fractions. The main outcomes recorded were RT toxicity
(graded using CTCAE v. 3.0 and RTOG/EORTC late scoring
criteria), response, relapse-free survival, and overall survival.
Results: Ninety patients were identified as having undergone radi-
cal-intent thoracic RT, with a median potential follow-up of 4.2
years. Fifty-seven patients (63%) were treated with hyperfraction-
ated accelerated RT, and 33 (37%) were treated with conventional
fractionation. Forty-six patients (51%) received PCI. Patients receiv-
ing hyperfractionated accelerated RT compared with conventional
fractionation had higher rates of grade 3 and 4 esophagitis (14%
versus 6%; p  0.312), a higher rate of treatment interruptions
(12% versus 3%; p  0.250), and a higher hospital admission rate
(39% versus 15%; p  0.031). The majority of patients were able to
complete the planned treatment, and there were no treatment-related
deaths. Median survival for all patients from commencement of RT
was 14.2 months (95% confidence interval [CI]: 11.9–18.1 months),
and survival at 2 years was 24.8% (95% CI: 16.9–35.0%). On
multifactor analysis, the only factor associated with longer survival
was PCI (hazard ratio  0.40; p  0.001).
Conclusions: Hyperfractionated accelerated RT was more toxic
than conventional fractionation, but it was possible to deliver treat-
ment as planned in the majority of patients. PCI was associated with
improved survival. Both treatments can be incorporated into routine
practice.
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(J Thorac Oncol. 2007;2: 506–513)
Small-cell lung cancer (SCLC) is an aggressive neuroen-docrine cancer that accounts for 14% of new primary lung
malignancies.1 Originally, chemotherapy was primarily used
because of the high risk of systemic metastasis. The addition
of thoracic radiotherapy (RT) to chemotherapy in patients
with limited disease (LD) has been shown in a meta-analysis
to increase overall survival (OS).2
Conventional thoracic RT has usually consisted of
2-Gy fractions, delivered once daily for 4 to 5 weeks (40–50
Gy). A study by Turrisi et al.,3 initially reported in 1998 and
published the following year, demonstrated a survival advan-
tage for hyperfractionated accelerated RT compared with
conventionally fractionated RT in patients with LD SCLC.
Despite a biologically equivalent lower dose, the shorter,
hyperfractionated accelerated regimen of 45 Gy in 30 frac-
tions during 3 weeks demonstrated a 10% difference in OS at
5 years compared with a 5-week schedule. Nevertheless, the
hyperfractionated accelerated regimen was associated with a
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25% incidence of acute grade 3 esophagitis compared with
5% with once-daily RT. This may have resulted in limited use
of this schedule, particularly at centers without specialized
nutritional support or where there are practical difficulties in
delivering hyperfractionated accelerated RT treatment.
The risk of brain metastasis is high in patients with
SCLC, with an average reported incidence of 25%.4 This
observation has led to a number of trials evaluating the effects
of prophylactic cranial irradiation (PCI). A meta-analysis of
these trials, initially reported by Auperin et al.5 in 1998 and
published the following year, not only confirmed a reduction
in risk of brain metastasis associated with PCI but also
revealed a statistically significant 5.4% increase in OS at 3
years (20.7% versus 15.3%) in patients who had achieved a
complete response (CR).
On the basis of these reports, in 1998, twice-daily
thoracic RT replaced our standard conventional fractionation
schedule of 50 Gy,6 and PCI was introduced at the Peter
MacCallum Cancer Centre (Peter Mac). We undertook this
review to establish that administration of both hyperfraction-
ated accelerated thoracic RT and PCI are feasible outside the
trial setting, and to assess their effects on toxicity and sur-
vival.
PATIENTS AND METHODS
Patients eligible for the retrospective review had to
have a histologically confirmed diagnosis of LD SCLC and to
have been planned for a radical course of thoracic RT
between June 1998 and May 2002. The commencement date
was chosen because that was when the policies of (1) offering
hyperfractionated accelerated thoracic RT, and (2) recom-
mending PCI to patients achieving CR, were adopted by the
Peter Mac Lung Service. Patients had to be between 18 and
80 years of age and to have limited-stage disease, defined as
disease confined to one hemithorax with or without medias-
tinal node metastasis and with or without ipsilateral or bilat-
eral supraclavicular node metastasis.7 Patients with metastatic
disease or prior chest irradiation were ineligible.
Staging procedures included history, physical examina-
tion, computed tomography (CT) of the thorax, upper abdo-
men and brain, and a whole-body bone scan. Staging with
positron emission tomography (PET) was not routinely per-
formed.
All patients had to have been planned to receive che-
motherapy, and this usually consisted of a combination of
carboplatin and etoposide, for a total of four to six cycles.
When chemotherapy was administered concomitantly with
RT, cisplatin was substituted for carboplatin to reduce the
risk of myelosuppression.
RT Details
RT was delivered with megavoltage energy (6 MV)
using three-dimensional conformal techniques; it usually in-
volved a three- or four-beam arrangement, delivered over two
phases (phase 1 delivered 30–40 Gy by an anteroposterior
beam arrangement, and phase 2 delivered the remaining
10–15 Gy using an opposed–oblique pair, avoiding the spinal
cord). The spinal cord–dose constraint was a maximum of 45
Gy at any point. Where possible, the mean lung dose was kept
below 20 Gy, and the V20 (proportion of the lung receiving
20 Gy or less after subtracting the gross tumor volume) was
less than 35%. Gross tumor volume was based on the pre- or
postchemotherapy volume. The clinical target volume in-
cluded the gross tumor volume with a 1.5-cm margin. Unin-
volved regional lymph nodes were not treated electively. The
planning target volume included the clinical target volume
with an additional margin determined by the amount of
cardiorespiratory movement, as assessed using fluoroscopy.
All eligible patients were planned to receive a radical course
of RT, and received at least one fraction. The RT regimens
used at Peter Mac were classified into two groups:
1. Conventional fractionation group: defined as 50 Gy in
25 fractions, delivered once daily for 5 weeks.
2. Hyperfractionated accelerated RT group: defined as 45
Gy in 30 fractions, delivered twice daily (minimum 6
hours apart) for 3 weeks.
Although the institutional policy was to recommend
twice-daily fractionation, a number of patients were treated
during this period with daily fractionation. Some patients
opted to have the daily schedule because of practical diffi-
culties involved in attending twice per day, and intermittent
increases in departmental workload sometimes mandated pre-
scription of the less demanding daily schedule.
The RT was usually delivered concomitantly with che-
motherapy, preferentially given early in the course of che-
motherapy. Some patients received RT delivered sequentially
on completion of their chemotherapy.
PCI
Patients who achieved a CR to chemotherapy and RT
were considered for PCI. The dose delivered was 36 Gy in 18
fractions, given once daily for 3 weeks, using opposed lateral
beams encompassing the entire cranial contents. The dose
chosen was based on an analysis suggesting that it was
associated with an approximate 70% reduction in risk of brain
metastasis.8
Endpoints
The primary endpoint of this study was toxicity from
thoracic RT, and secondary endpoints were response, relapse-
free survival (RFS), and OS.
Toxicities
Acute radiation toxicities were graded using NCI CT-
CAE v. 3.0 criteria9 and were assessed from the first day of
RT to 90 days after RT. Only esophageal and pulmonary
toxicity were assessed. Late RT toxicities for esophagus and
lung were also recorded and were graded by RTOG/EORTC
late scoring criteria.10
We defined other surrogate measures of thoracic RT
toxicity:
1. Failure to complete the planned RT course.
2. Interruptions to the delivery of RT, defined as a treat-
ment break of 1 day or more.
3. Need for hospitalization.
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Disease Outcomes
Disease endpoints assessed in the study included first
site of relapse, with emphasis on the brain. RFS was mea-
sured from the commencement of RT treatment to first
relapse at any site or until death from any cause. Freedom
from brain relapse (FFBR) was measured from the com-
mencement of RT treatment to first relapse in the brain only.
Response assessment included a CT chest and abdomen scan
6 to 8 weeks after completion of RT, using RECIST criteria11
to grade response. PET was used if available. All patients
being considered for PCI received a CT or MRI of the brain
to exclude cerebral metastasis.
Follow-up usually occurred at 3 monthly intervals.
There were no standard follow-up tests, because many pa-
tients were referred for RT from outside sources (private
oncologists, other hospitals), and investigations were at the
discretion of the referring unit. OS was measured from the
commencement of RT treatment to the date of death from any
cause.
Statistical Methods
Patients were followed to a study closeout date of
November 9, 2004.
The potential follow-up time was calculated using the
reverse Kaplan–Meier method.12
Patient baseline characteristics and details of treatment
received were summarized using descriptive statistics, which
included the median and range for items measured on a
continuous scale, and counts and percentages for categorical
items. Measures of thoracic radiation toxicity were summa-
rized using descriptive statistics. When appropriate, a com-
parison between the two RT groups (hyperfractionated accel-
erated versus conventional fractionation) was made using the
two-sided Fisher exact test, Cochran–Armitage test for trend,
Pearson chi-square test, or the Mann–Whitney test.12
Prognostic factors stipulated for time to event analyses
included RT group (hyperfractionated accelerated versus con-
ventional fractionation), gender, age (65 versus 65), PCI
(no versus yes), weight loss (no versus yes), tobacco smoker
(never/ex versus current), Eastern Cooperative Oncology
Group performance status, staging PET (no versus yes),
timing of chemotherapy with RT (sequential versus concur-
rent and concurrent early; first two cycles versus concurrent
late; three or more cycles), and response to RT.
The Kaplan–Meier product-limit method was used for
time-to-event analyses, with censoring of event times at the
closeout date for those patients who were event free at that
date or the date of last contact for those patients who were
lost to follow-up.13 Ninety-five-percent CIs were estimated
using the Brookmeyer-Crowley method for median event
times and the logit transformation for event rates.13 Differ-
ences or trends between groups were tested using the Mantel-
Cox log-rank test.13 Relative hazard rates were calculated
using the Cox proportional hazards model.14
Multifactor analysis for OS was carried out using the
Cox proportional hazards model and a stepwise procedure14
to identify independent prognostic factors. The removal and
entry levels of significance were 0.05 and 0.01, respectively.
Patients with unknown values of any prognostic factor were
excluded from the multifactor analysis.
All p values are two sided, and no adjustments have
been made for multiple comparisons.
RESULTS
Ninety patients were identified as eligible for inclusion
on this retrospective study. Characteristics of the eligible
patients are shown in Table 1.
Thoracic RT
Fifty-seven of 90 patients (63%) received hyperfrac-
tionated accelerated RT, and 33 (37%) were treated with
conventionally fractionated RT. V20 was recorded for 62
patients (69%). The median value for V20 was 23% (range:
4–58%). Mean lung dose was recorded for 31 patients (34%),
with a median value of 11.6 Gy (range: 2.7–21.8 Gy).
Chemotherapy
Ninety-four percent of patients (n  85) received the
combination of carboplatin with etoposide (Table 2). The
majority (97%) received four to six cycles. Thoracic RT was
given concurrently with chemotherapy in 87% of patients
TABLE 1. Patient Baseline Characteristics
All
Patients
(n  90)
Hyperfractionated
Accelerated
Radiotherapy
(n  57)
Conventional
Fractionation
(n  33)
Sex
Male 63% 63% 64%
Female 37% 37% 36%
Age at diagnosis
Median 65 65 64
Range 48–81 50–81 48–76
ECOG PS
0 36% 28% 48%
1–2 58% 65% 45%
Not documented 7% 7% 7%
Weight loss
None 47% 47% 45%
10% 24% 25% 24%
10% 6% 5% 6%
Not documented 23% 23% 24%
Site of tumor involvement
Lung parenchymal lesion 50% 47% 55%
Ipsilateral hilar nodes 60% 60% 61%
Mediastinal nodes 61% 61% 58%
Supraclavicular nodes 9% 4% 18%
Staging investigations
CT chest 100% 100% 100%
CT abdomen 67% 58% 82%
CT brain 78% 75% 82%
Nuclear bone scan 81% 81% 82%
PET scan 13% 14% 12%
ECOG PS, Eastern Cooperative Oncology Group performance status; CT, com-
puted tomography; PET, positron emission tomography.
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(n  78), and in the remaining patients (n  12), RT was
delivered sequentially after chemotherapy completion. Al-
though it was institutional protocol for patients to receive
concurrent therapy, some patients were only referred by their
outside medical oncologist for RT after chemotherapy com-
pletion. For the patients who received their RT concurrently
with chemotherapy, 44% of patients (34/78) received RT
early within the first or second cycle.
PCI
Forty-six of the 90 patients (51%) received PCI. Sev-
enty-six patients (84%) had documented treatment responses
after definitive chemotherapy and thoracic RT. Sixty-four of
76 patients achieved a CR to treatment (84%). Thirty-nine
patients (61%) achieving CR received PCI, and 25 patients
did not receive PCI (39%).
Thoracic Radiation Toxicity
Ten patients (11%) were documented with acute grade
3 or 4 esophagitis (eight hyperfractionated accelerated pa-
tients and two conventionally fractionated patients; p 
0.312). Only three cases of pneumonitis (3%) were docu-
mented, all grade 3, and all received hyperfractionated accel-
erated RT (Table 3). There were no treatment-related deaths
and no documented reports of any grade 3 or 4 late esopha-
geal or pulmonary toxicity.
Failure to Complete RT
Five of 90 patients did not complete the planned RT
dose (Table 4). Ninety-eight percent of patients (56/57)
completed hyperfractionated accelerated RT, and 29/33 (88%)
completed conventionally fractionated RT (p 0.059). Reasons
TABLE 2. Chemotherapy Details
All Patients
(n  90) %
Hyperfractionated
Accelerated
(n  57) %
Conventional
Fractionation
(n  33) %
Agents
Carboplatin  etoposide 94 91 100
Other 6 9 0
Total number of cycles received
4 43 49 33
5 9 7 12
6 44 39 55
Other 4 5 0
Relationship to radiotherapy
Sequential 13 12 15
Concurrent 87 88 85
Chemotherapy cycle where radiotherapy was
delivered concurrently
1 8 10 4
2 36 44 22
3 33 28 42
4 21 16 28
Other 2 2 4
TABLE 3. Acute Esophageal and Pulmonary Toxicity
All Patients
(n  90)
Hyperfractionated
Accelerated
(n  57)
Conventional
Fractionation
(n  33)
n % n % n % p Valuea
Esophagitis 0.312
Grade 3 9 10 7 12 2 6
Grade 4 1 1 1 2 0 0
Pneumonitis 0.292
Grade 3 3 3 3 5 0 0
Grade 4 0 0 0 0 0 0
a Fisher’s exact test.
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for not completing RT included treatment-related toxicity (3),
non–treatment-related toxicity (1), and patient choice (1).
Interruption to RT Delivery
Ten patients (11%) had an interruption in their thoracic
RT treatment, of whom eight received hyperfractionated
accelerated RT and two received conventional fractionation
(p  0.315), but they all still completed the planned dose. Of
the 10 patients, five patients had delays attributable to treat-
ment-related toxicity, and the remaining five had delays
attributable to non–treatment-related reasons.
Hospitalization
Twenty-seven of 90 patients (30%) were hospitalized at
least 1 day during the period of RT and up to 3 months after
its completion, including 22/57 (39%) of those given hyper-
fractionated accelerated RT and 5/33 (15%) of those given
conventionally fractionated RT (p  0.031). Median time
hospitalized was 10.5 days (range: 2–46 days) for the 22
patients receiving hyperfractionated accelerated RT and 4
days (range: 3–5 days) for the five patients receiving conven-
tionally fractionated RT. For those who received hyperfrac-
tionated accelerated treatment, 86% (19/22) were admitted
into the hospital for treatment-related toxicity.
Site of First Relapse
By the closeout date, 61 patients (68%) had relapses,
eight patients (9%) were still alive with no relapses reported,
for 17 patients (19%) it was not known whether relapses had
occurred before death, and four patients were lost to follow-
up. Of the 61 patients known to have had relapses, the
majority relapsed in distant sites (n  37) (Table 5).
Fourteen patients relapsed in the brain only as the first
site of relapse (16%). All 14 patients had CR from the
combined-modality therapy. Three of these patients relapsed
in the brain after receiving PCI (3/397%) compared with 11
of 25 (44%) patients who did not receive PCI (p 0.001). Of
the 17 patients whose relapse status was unknown, five
patients had received PCI.
RFS and OS
The median potential follow-up time was estimated at
4.2 years (95% confidence interval [CI]: 3.0–5.2 years). The
analysis of RFS included those 69 patients for whom both
relapse status and date of relapse were known, with the
median RFS estimated at 8.0 months (95% CI: 6.8–11.1
months).
The FFBR rate was estimated at 78% (95% CI: 63.1–
88.0%) at 12 months and 69.4% (95% CI: 51.8–82.7%) at 24
months. For patients who did not receive PCI, the FFBR rate
was estimated at 44.7% (95% CI: 21.9–70.0%) at 12 months
and 35.7% (95% CI: 15.1–63.5%) at 24 months, compared
with 95.5% (95% CI: 73.9–99.4%) at 12 months and 88.1%
(95% CI: 61.7–97.2%) at 24 months for patients who re-
ceived PCI (p  0.001).
Of the 90 patients included in the analysis of OS, 73
patients died before the closeout date, 13 were still alive, and
4 were lost to follow-up. Median OS was estimated at 14.2
months (95% CI: 11.9–18.1 months), and the Kaplan–Meier
curve is shown in Figure 1.
Unifactor analyses on prognostic factors for OS in-
dicated that improved OS was associated with receiving
PCI (p  0.001) (Figure 2) and having a response to
treatment (p  0.001). Notably, receiving hyperfractionated
accelerated RT versus conventionally fractionated RT was
not significant (p  0.457). Regarding the timing of chemo-
TABLE 5. Site of First Relapse
All Patients (n  90)
Site of First Relapse n %
Distant metastasisa 37 41
Thorax alone 10 11
Brain alone 14 16
Unknown 17 19
No relapse 12 13
a Four patients in this group had brain relapses at the same time as other distant
metastases.
TABLE 4. Other Surrogate Measures of Thoracic Radiation Toxicity
All Patients
(n  90)
Hyperfractionated
Accelerated
(n  57)
Conventional
Fractionation
(n  33)
n % n % n % p Value
Completed radiotherapy 85 94 56 98 29 88 0.059a
Radiotherapy treatment interruption 10 11 8 14 2 6 0.315a
Hospitalization 27 3 22 39 5 15 0.031a
Number of days hospitalized
Median 8 10.5 4 0.036b
Range 2–46 2–46 3–5
Hospitalization treatment related 22 81 19 86 86 60 0.221a
Not hospitalization treatment related 5 19 3 14 14 40
a Fisher exact test. b Mann–Whitney test.
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therapy with RT, receiving sequential RT versus concurrent
RT was not significant (p  0.528), and receiving RT with
the first two chemotherapy cycles (early) versus RT with the
third or later cycle (late) also was not significant (p  0.989).
On multifactor analysis of OS, only PCI was significant
with a survival advantage if PCI was received (hazard ratio:
0.40; 95% CI: 0.24–0.64; p  0.001). For the 64 patients
who achieved a CR to chemotherapy and RT, the median
survival in the patients who received PCI was 21.1 months
(95% CI: 14.9–48.6 months) compared with 14.0 months
(95% CI: 8.5–19.9 months) in patients who did not receive
PCI (p  0.031) (Figure 3).
DISCUSSION
This study has demonstrated that evidence-based inten-
sive RT treatment schedules for LD SCLC can be introduced
into routine practice in the setting of a large, busy, dedicated
cancer center.
In our review, the rate of acute grade 3 or 4 esophagitis
in the hyperfractionated accelerated cohort was 14% com-
pared with 6% in the conventionally fractionated cohort.
Despite the limitations in assessing toxicity retrospectively,
the rate is lower than the 25% grade 3 esophagitis rate
reported in the study by Turrisi et al.3 Other randomized trials
using twice-daily RT have reported similarly low rates of
esophagitis, including 9 and 12%.15,16 Possible explanations
for this lower rate of esophageal toxicity compared with
Turrisi et al.’s3 experience include the different intensity of
chemotherapy,16 variations in esophageal mucosa or diet
attributable to the patient’s country of origin, and disparities
in radiation planning and delivery.17 A split-course twice-
daily regimen incorporating a 2.5-week break in the trial
reported by Schild et al.15 may explain the lower rate of
esophagitis. One plausible explanation for the higher toxicity
seen in Turrisi et al.’s3 study was the RT target volume,
which not only included the gross tumor; the ipsilateral hilar
lymph nodes and bilateral mediastinal nodes also were elec-
tively irradiated. The inferior extent of the field “extended 5
cm below the carina or to a level including the ipsilateral hilar
structures, whichever was lower”3; this would have encom-
passed a significant length of esophagus. The optimal target
volumes for RT have not been defined. At our center, the
planning target volume included the gross tumor (before or
after chemotherapy), with at least a 1.5-cm margin and a
margin for cardiorespiratory movement but no elective irra-
diation of uninvolved hilar or mediastinal nodes. The im-
provement in quality of diagnostic and planning CT, use of
three-dimensional treatment planning, and the use of PET
FIGURE 1. Kaplan–Meier curve of overall survival from the
start of radiotherapy. Ninety-five-percent confidence inter-
vals are shown by dotted lines. Patients with censored times
are shown by tick marks.
FIGURE 2. Kaplan–Meier curve of overall survival compar-
ing patients who received prophylactic cranial irradiation
(PCI) versus no PCI. Patients with censored times are shown
by tick marks.
FIGURE 3. Kaplan–Meier curve of overall survival in a co-
hort who achieved a complete response (CR) to combined-
modality therapy, comparing patients who received prophy-
lactic cranial irradiation (PCI) versus no PCI. Patients with
censored times are shown by tick marks.
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scanning in staging18 may permit more accurate delineation
of disease extent and reduction of target volumes.
A higher proportion of patients receiving hyperfraction-
ated accelerated RT had interruptions in their treatment. More
patients in the hyperfractionated accelerated RT cohort re-
quired hospitalizations: 39% compared with 15% in the
conventional fractionation group, with a median stay that was
6 days longer than that of the conventional fractionation
group (10.5 days versus 4 days). Regardless, the majority of
patients completed their thoracic RT whether it was delivered
once or twice per day. The higher frequency of hospitaliza-
tions (the majority being treatment related) and longer
median stay substantiate the need for regular monitoring of
patients during hyperfractionated accelerated RT, early
management of toxicities, and the availability of inpatient
services.
OS in patients with limited-stage disease remains poor,
although a proportion become long-term survivors. Median
OS for the entire cohort was estimated at 14.1 months,
measured from commencement of RT. Higher median sur-
vival has been reported in the randomized trials, ranging from
19 to 27 months,3,15,16 but in these studies, survival was
measured from registration or randomization. A retrospective
review from another Australian center showed similar median
survival of 15 months.19 The lower reported survival rates
may reflect the difference in daily clinical practice versus a
prospective clinical trial. For example, patient selection may
be less rigorous,20 and not all patients in our review had
complete staging investigations. Not all patients achieving
CR received PCI; this may have reduced the survival of the
group as a whole.
The only prognostic factor for survival on multifactor
analysis was the administration of PCI. Since the meta-
analysis, it has been standard practice at our center to rec-
ommend PCI to complete responders at the completion of
chemotherapy. Nevertheless, not all patients received it, ei-
ther because of poor recovery after combined-modality ther-
apy or because of patient refusal. Considering only the
patients who achieved CR, the median survival was 7 months
longer in the group who received PCI (21 months versus 14
months). The longer survival in this select subgroup may be
a consequence of selection bias (if only the fitter patients
received PCI), or it could be a consequence of the PCI dose
used by our group, which is generally higher than the doses
used in the trials included in the meta-analysis.5
Although the majority of the patients in this study
suffered a distant relapse as their first site, of the 64 patients
who achieved CR, 44% relapsed in the brain if they did not
receive PCI, as compared with 7% of those who did receive
PCI. The brain metastasis relapse rate after PCI is low
compared with the rates reported in the meta-analysis. This
could be attributable to the retrospective nature of this study
or to differences in follow-up. Nevertheless, another possible
explanation is the dose used at Peter Mac: 36 Gy in 18
fractions. The randomized trials of PCI used various regi-
mens consisting of a single 8-Gy dose, 24 Gy in 8 fractions,
24 Gy in 12 fractions, 30 Gy in 10 fractions, or 36 Gy in 18
fractions. The benefit of a higher dose is supported by the
meta-analysis, which showed a trend toward a lower risk of
brain metastasis as the radiation dose was increased. Con-
cerns have been raised about the impact on cognitive function
and quality of life after PCI, but studies, both prospective and
retrospective, have failed to show any consistent effect.4,21,22
Against these concerns should be weighed the undoubted
survival benefit associated with PCI,5 which we also have
observed. Toxicity from PCI was not evaluated in this study.
Ongoing randomized trials should clarify the optimal dose of
PCI as they are designed to evaluate the impact of various
dose schedules not only on metastasis rate but also on
neurocognitive function.
In summary, on the basis of our retrospective review,
the use of hyperfractionated accelerated thoracic RT is safe,
tolerable, and deliverable outside the setting of a clinical trial.
Further, our study supports the existing high level of evidence
of a survival advantage associated with PCI. That PCI proved
to be the most important determinant of survival in this
relatively small retrospective series may be a consequence of
the greater efficacy of a higher PCI dose. Indeed, PCI seemed
to be a necessary prerequisite if there was to be any prospect
of long-term survival.
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